Alto Neuroscience (NYSE:ANRO) Shares Gap Up – Should You Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) shares gapped up prior to trading on Monday. The stock had previously closed at $21.87, but opened at $25.82. Alto Neuroscience shares last traded at $26.9530, with a volume of 73,040 shares trading hands.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ANRO. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Zacks Research upgraded Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. HC Wainwright raised their target price on Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Monday, October 19th. Wedbush boosted their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Finally, BTIG Research upped their price target on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.88.

Alto Neuroscience Stock Performance

The stock’s 50-day moving average price is $26.71 and its 200-day moving average price is $24.43. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -11.88 and a beta of 1.42.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.13. As a group, equities research analysts expect that Alto Neuroscience, Inc. will post -2.69 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Nicholas Smith sold 24,056 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the sale, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at approximately $621,229.20. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 11.25% of the company’s stock.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds have recently bought and sold shares of the stock. Sterling Capital Management LLC lifted its stake in shares of Alto Neuroscience by 1,045.7% during the third quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock valued at $27,000 after buying an additional 962 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Alto Neuroscience by 48,581.8% during the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock worth $137,000 after purchasing an additional 5,344 shares during the last quarter. GK Wealth Management LLC acquired a new stake in shares of Alto Neuroscience during the second quarter worth $226,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Alto Neuroscience in the first quarter valued at $534,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Alto Neuroscience in the first quarter valued at $538,000.

Alto Neuroscience Company Profile

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.